Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

– Topline data from second pivotal Phase 3 trial of lefamulin for CABP (LEAP 2) expected in Spring 2018 – – $90 million cash and investments as of March 31, 2018 expected to fund operations into the first quarter of 2020 – DUBLIN, Ireland , May 08, 2018 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc

READ FULL TEXT

Leave a Reply

Your email address will not be published.